NasdaqGS:WGSHealthcare
A Look At GeneDx Holdings (WGS) Valuation After Guidance Cut And First Quarter 2026 Results
GeneDx Holdings (WGS) is back in focus after first quarter 2026 results showed revenue of US$102.25 million, a net loss of US$63.32 million, and a cut to full year revenue guidance.
See our latest analysis for GeneDx Holdings.
The latest earnings release and guidance cut came alongside sharp share price swings, with a 16.68% 1 day share price return but a 69.39% year to date share price decline. At the same time, the 3 year total shareholder return remains very large, suggesting recent...